CASTL Announces Location for Quebec Biomanufacturing Training Facility

The Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced its expansion into Quebec with the location of their future Biomanufacturing Training Facility in Montreal. Located at 4100 Molson Street, in the heart of the Technopôle Angus, the new 4544 square foot training facility will contain leading-edge pilot-scale bioprocessing equipment that will allow employees to gain practical skills that are immediately transferable to process scale-up and clean room environments. The facility will be equipped with laboratories and classroom spaces built to deliver the highest quality bioprocessing training. With this new facility, CASTL can deliver on-site customized hands-on and theoretical training for entry-level employees through to senior management and post-secondary students....READ MORE

InMed Provides Business Update and Milestones for 2023

InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, outlines key accomplishments from 2022 and provides business update and catalysts for 2023. Highlights include:

• Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023
• Progress preclinical research in glaucoma in preparation for human trials
• Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s...READ MORE

Molecular You Launches a New Preventive Solution Shown to Improve Health Outcomes Over 100 Days

Molecular You announced the launch of its preventive digital health solution, based on a new type of blood test that leverages their expertise in biomarker analysis. Results of a recent pilot involving 122 participants, shows over 50% average risk reduction for areas including cardiovascular disease, diabetes, and cognitive health after following the recommended interventions for 100 days...READ MORE

Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes

Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced that significant progress has been achieved in its collaboration with Evotec SE. This progress includes advancement of Evotec’s iPSC derived islet-like clusters in combination with Sernova’s implantable Cell Pouch™ device toward a first-in-human Phase 1/2 clinical trial for the treatment of patients with T1D and severe hypoglycemia slated for regulatory filing in 2024. The objective of the collaboration is to produce an off-the-shelf, commercially viable, ethically derived cell therapy treatment for people suffering from T1D...READ MORE

QULIPTA™ Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults

AbbVie announced that Health Canada has approved QULIPTA (atogepant) for the prevention of episodic migraine (< 15 migraine days per month) in adults.1 QULIPTA, the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) preventive treatment, marks the latest innovation in AbbVie’s migraine portfolio to support Canadians impacted by migraine...READ MORE

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, is pleased to announce that it is planning a 180 patient, 90-day Phase 2b clinical study of NP-120 (“Ifenprodil”) for chronic cough to begin in Q3 of 2023. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B), which prevents glutamate signaling. Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough...READ MORE

Cutting Edge Technology Treats First Patient in Kelowna

Patients receiving cancer care in Kelowna are the first in Canada to receive advanced radiation therapy using the latest treatment technology. The device, called Ethos, uses artificial intelligence (AI) technology to adapt to daily changes in the shape and position of cancer tumours, allowing clinicians to better target the treatment and dramatically spare the healthy tissue from the side effects of radiation...READ MORE

Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne

Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, announce that in a preclinical trial run by the Dr. George Lui lab at the University of California San Diego School of Medicine, one of its topical lead compounds produced significant inhibitory effects in an animal model of acne, a common chronic inflammatory skin disease for which there is a significant unmet need...READ MORE

Izotropic Releases First Video of IzoView

Izotropic Corporation, a medical device company commercializing IzoView, a dedicated breast CT (computed tomography) imaging platform, for the more accurate detection and diagnosis of breast cancers, is pleased to release the first video showcasing the completed engineering of IzoView. This video is the first in a series of presentations, interviews, and demonstrations of IzoView and its capabilities...READ MORE

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, today outlined recent progress in its clinical programs and key milestones for 2023.

• XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures
• Strong financial position expected to fully support XEN1101 Phase 3 program development and cash runway into 2026...READ MORE

Nimbus Synergies Appoints New Board Member Michael Ball to Enhance Leadership in Canadian Health Tech

Nimbus Synergies, investor, partner, and mentor to Canada’s most promising health technology companies, is pleased to announce the appointment of Michael Ball to the Board of Directors of Discovery Parks and Nimbus Synergies. Michael was also appointed to Nimbus’ Health Tech Investment Committee. Michael Ball is an industry veteran with over 30 years of global business experience leading and scaling innovative healthcare start-ups to exit through C-suite, board, and advisory roles...READ MORE

Domain Therapeutics Announces First Patient Cosed with DT-9081 in Phase I Clinical Study in Patients with Advanced, Recurrent or Metastatic Solid Tumors: The EPRAD Study

Domain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), announces that the first patient has been dosed with DT-9081, Domain’s proprietary IO asset, in a first-in-human Phase I study. DT-9081 is an oral small molecule product which, by blocking the EP4 receptor present on immune cells, is able to reverse the prostaglandin E2 (PGE2)-mediated immunosuppression triggered by some tumors to bypass the immune system...READ MORE

Variational AI Files Two US Provisional Patents for Potential COVID-19 Drug Created by Generative AI

Variational AI, developer of the Enki™ generative AI drug discovery platform to redefine the economics of drug development, announced that the company has filed two provisional patents with the USPTO related to new chemical entities (NCE) successfully created using generative AI. Variational AI’s protease inhibitors are among the first NCEs created via a purely generative model and will be useful in the development of COVID-19 drugs as part of the company’s coronavirus antiviral program. Of even greater significance, this method underscores the potential of generative AI to create novel, efficacious, safe, and synthesizable molecules...READ MORE

Wex Pharmaceuticals Inc. Enrolls the First Patient in The Phase 2b Clinical Trial Evaluating the Efficacy and Safety of Halneuron(R) In the Treatment of Chemotherapy-Induced Neuropathic Pain

WEX Pharmaceuticals Inc., a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that the first patient has been dosed in its Phase 2B clinical trial evaluating the efficacy and safety of Tetrodotoxin in the treatment of Chemotherapy-Induced Neuropathic Pain.

The Clinical Trial is a randomized, double-blind, placebo-controlled, multinational, multicenter study evaluating the efficacy and safety of Halneuron® in 222 patients with moderate-to-severe Chemotherapy-Induced Neuropathic Pain...READ MORE

Government of Canada Introduces the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans – TCPS 2 (2022)

The Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), and the Social Sciences and Humanities Research Council of Canada (SSHRC) are pleased to announce the release of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans – TCPS 2 (2022). TCPS 2 (2022) replaces TCPS 2 (2018) as the official human research ethics policy of the three federal research funding agencies...READ MORE

Associate Scientist/Scientist, Chemistry

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies- one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options.

LEARN MORE

Assay Development Scientist

Gandeeva Therapeutics, Inc. is a rapidly growing precision biotechnology company located in Greater Vancouver harnessing the power of cryo-EM technology and machine learning to advance drug discovery and development at scale. Their unique and world-leading AI-enabled cryo-EM drug discovery platform combines deep biochemical and structural knowledge to target the most important protein sites and translates this knowledge into superior precision medicines for patients. Gandeeva are seeking a highly motivated Assay Development Scientist to join the Assays team and actively develop and implement assays to support Gandeeva drug discovery programs.

LEARN MORE

Computational Scientist, Drug Design

Gandeeva are expanding their interdisciplinary and innovative team of biologists, chemists, microscopists, engineers, software developers and business professionals who work closely together in a state-of-the-art facility that provides a stimulating environment and reflects t inclusive and welcoming culture.

The Computational Scientist will focus on developing and applying AI/ML approaches to small molecule design to support Gandeeva’s drug discovery programs. This role involves both the development of innovative computational methods as well as the application/evaluation of established methods towards the invention of novel medicines.

LEARN MORE

Biogen Canada was established in Mississauga, Ontario in April 1998 and has been conducting business in Canada for more than 20 years. The scope of their operations has continued to expand and has helped to improve the care of individuals affected by multiple sclerosis (MS) and spinal muscular atrophy (SMA).

There are currently 8 therapy areas where Biogen is doing research in Canada, including: MS, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) or Lou-Gehrig disease, large hemispheric infarction, Parkinson’s Disease, progressive supranuclear palsy, SMA and pain.

Visit Website

Sustained Therapeutics is an early-stage company utilizing its advanced clinical and research expertise to develop non-opioid locally injected sustained-release therapeutics primarily for the treatment of pain. Their novel sustained-release drug delivery platform has the potential to provide effective, long-lasting solutions for managing both acute and chronic pain.

Sustained Therapeutics’ patented drug delivery platform is a non-opioid approach designed to relieve acute and chronic pain in a highly controlled way over longer periods with fewer side effects. Sustained's products have a significant competitive advantage, offering up to four weeks of pain relief from a single injection compared to only one to three days for competitive products. In addition they are non-addictive, unlike opioid drugs.

Visit Website